SI-BONE (NASDAQ:SIBN) Given Market Outperform Rating at JMP Securities

JMP Securities reiterated their market outperform rating on shares of SI-BONE (NASDAQ:SIBN - Free Report) in a report published on Tuesday, Benzinga reports. They currently have a $32.00 target price on the stock.

A number of other analysts have also weighed in on SIBN. Truist Financial reissued a buy rating and issued a $24.00 price target (down previously from $26.00) on shares of SI-BONE in a report on Tuesday, February 27th. Piper Sandler initiated coverage on SI-BONE in a research report on Thursday, March 28th. They set an overweight rating and a $25.00 price target on the stock. Needham & Company LLC restated a buy rating and issued a $27.00 price target on shares of SI-BONE in a research note on Tuesday. Morgan Stanley decreased their price target on shares of SI-BONE from $26.00 to $25.00 and set an overweight rating on the stock in a research note on Tuesday. Finally, Cantor Fitzgerald restated an overweight rating and issued a $25.00 target price on shares of SI-BONE in a research report on Tuesday, February 27th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of Buy and a consensus target price of $27.29.

SI-BONE Stock Up 8.3 %

NASDAQ SIBN traded up $1.20 during trading on Tuesday, reaching $15.68. The company's stock had a trading volume of 595,426 shares, compared to its average volume of 432,549. The stock has a market capitalization of $646.02 million, a PE ratio of -13.54 and a beta of 1.24. SI-BONE has a 1-year low of $13.96 and a 1-year high of $29.51. The business has a 50-day moving average price of $15.87 and a 200-day moving average price of $18.02. The company has a current ratio of 9.01, a quick ratio of 8.15 and a debt-to-equity ratio of 0.21.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, February 26th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. SI-BONE had a negative net margin of 31.20% and a negative return on equity of 28.22%. The business had revenue of $38.86 million during the quarter, compared to analysts' expectations of $38.60 million. On average, research analysts forecast that SI-BONE will post -0.98 earnings per share for the current fiscal year.

Insider Buying and Selling at SI-BONE

In other news, CFO Anshul Maheshwari sold 2,425 shares of the business's stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total value of $37,466.25. Following the completion of the transaction, the chief financial officer now owns 205,516 shares in the company, valued at $3,175,222.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other SI-BONE news, insider Anthony J. Recupero sold 3,307 shares of the business's stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $15.50, for a total transaction of $51,258.50. Following the completion of the transaction, the insider now owns 252,453 shares in the company, valued at $3,913,021.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Anshul Maheshwari sold 2,425 shares of SI-BONE stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $15.45, for a total value of $37,466.25. Following the sale, the chief financial officer now directly owns 205,516 shares of the company's stock, valued at $3,175,222.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,905 shares of company stock valued at $190,273. 5.40% of the stock is currently owned by company insiders.

Institutional Trading of SI-BONE

Large investors have recently bought and sold shares of the stock. Victory Capital Management Inc. purchased a new position in SI-BONE during the fourth quarter worth approximately $6,721,000. Brown Advisory Inc. raised its position in SI-BONE by 5.4% in the fourth quarter. Brown Advisory Inc. now owns 4,207,703 shares of the company's stock valued at $88,320,000 after purchasing an additional 214,089 shares during the period. Wellington Management Group LLP increased its position in shares of SI-BONE by 34.9% during the fourth quarter. Wellington Management Group LLP now owns 817,048 shares of the company's stock valued at $17,150,000 after acquiring an additional 211,209 shares during the last quarter. Assenagon Asset Management S.A. raised its position in SI-BONE by 92.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 419,940 shares of the company's stock valued at $8,815,000 after purchasing an additional 201,615 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in SI-BONE by 7.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,308,516 shares of the company's stock valued at $49,033,000 after acquiring an additional 155,121 shares during the period. Hedge funds and other institutional investors own 98.11% of the company's stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.